申请人:Allergan, Inc.
公开号:US09353093B2
公开(公告)日:2016-05-31
This invention is directed to a compound of Formula I
or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
本发明涉及一种I式化合物或其药学上可接受的盐,其中R1、R2、R3、R4、R5、R6、R7和X的定义如本文所述。I式化合物可用作受体酪氨酸激酶(RTK)抑制剂,并可用于治疗癌症、血管增生性疾病、纤维化疾病、系膜细胞增生性疾病和代谢性疾病等疾病。